

CURRICULUM VITAE

Daniela Drandi, PhD

Personal data

Place of birth: Torino, Italy
Sex: Female
Citizenship: Italian
Marital Status: Married

Professional records

2005-present Permanent position as Medical Research Technician at Department of Molecular Biotechnologies and Health Sciences, University of Torino. Division of Hematology c/o "Città della Salute e della Scienza" Hospital, Via Genova 3, 10126 Torino, Italy Fax: + 39-011-696 3737; Phone: + 39-011-633-6884

2004-2005 Post-doctoral fellow, Department of Experimental Medicine and Oncology, Division of Hematology, University of Torino.

2002-2004 Associated researcher at Dana-Farber Cancer Institute, Oncology Medicine Department, Harvard Medical School, Boston (MA) U.S.A.

1999-2002 Internship, Department of Experimental Medicine and Oncology Division of Hematology, University of Torino.

Education

10/2005 Postgraduate degree in Clinical Biochemistry, University of Pavia, Italy

4/2001 Master degree in Medical Biotechnology, University of Torino, Italy

Skills

Molecular biology techniques as PCR, qPCR, ddPCR, RT-PCR, arrayCGH, western blotting, southern blotting, FISH, nucleic acid isolation and manipulation, gene cloning.

Knowledge and experience in Windows 7-8, MS tools, in using programs and databases for sequence analysis (Blast, IgBlast, IMGT, DNASTAR, Chromas, CLC, GenePix, Clustal) and for statistical analysis (GraphPad, SPSS).

Scientific interests and expertise

- Molecular pathogenesis of lymphoid tumors: analysis of the oncogenes and tumor suppressor genes involved in tumor progression; prognostic implications of molecular lesions.
- Biological prognostic factors in Non-Hodgkin lymphoma and Waldenström Macroglobulinemia.
- Non invasive approaches for mutation detection by ddPCR in indolent Lymphomas
- Interactions between the neoplastic clone, tumor microenvironment and immune system in patients with chronic lymphocytic leukemia (CLL) and Multiple Myeloma.
- Molecular monitoring of Minimal Residual Disease by qualitative and quantitative PCR (qPCR and ddPCR) and impact of High throughput approaches (NGS) in the context of national and international clinical trials.
- Standardization of molecular technologies for MRD analysis: responsible for QC organization of digital PCR-based Minimal residual disease monitoring in lymphoma within the Italian MRD network and the Euro-MRD consortium.

Current research

- Molecular monitoring of Minimal Residual Disease by ddPCR in MCL and FL clinical trials.
- MYD88 and CXCR4 somatic mutation analysis by ddPCR.
- National and European standardization program of ddPCR and qPCR for minimal residual disease analysis
- Responsible for ISO9001 accreditation program for the molecular biology laboratory at the Hematology division c/o "Città della Salute e della Scienza" Hospital, Via Genova 3, 10126 Torino, Italy

Teaching

- Support in teaching Hematology at Medical Biotechnology School of the university of Torino. Frontal lessons, as support of the Medical Biotechnology master classes ("INT0637A - TERAPIE BIOTECNOLOGICHE IN EMATOLOGIA", INT0637 - TERAPIE BIOTECNOLOGICHE": 2-4 hours/year (2007-2020).
- Teaching Molecular pathogenesis of Multiple Myeloma at Theoretical and practical stage on Multiple Myeloma (2010-2013).
- Supervision of master degree students in Medical Biotechnology.

Memberships

Italian Lymphoma Foundation (FIL)

FIL Minimal Residual Disease (MRD) Network

European Hematology Association (EHA)

Member of the board of EuroMRD working group-European Scientific Foundation of Laboratory Hemato Oncology (ESLHO)

Turin University Research Technician community

Spoken languages

Italian: mother tongue

English: proficient in writing and speaking (B2 Level certificated)

Scientific Production

50 peer review Publications (1 in press)

>90 abstracts

Publications

1. **Daniela Drandi**, Martina Ferrante, Michela Borriero, Simone Ferrero. MYD88^{L265P} mutation detection by ddpcr: recommendations for screening and minimal residual disease monitoring. Clinical Applications of Nucleic Acid Amplification, Methods in Molecular Biology, Springer Nature. In press.
2. **D. Drandi**, P. Decruyenaere, M. Ferrante, F. Offner, J. Vandesompele, S. Ferrero. Nucleic acid biomarkers in Waldenström Macroglobulinemia and IGM-MGUS: current insights and clinical relevance. Diagnostics 2022, 12(4), 969.
3. Zaccaria GM, Ferrero S, Hoster E, Passera R, Evangelista A, Genuardi E, **Drandi D**, Ghislieri M, Barbero D, Del Giudice I, Tani M, Moia R, Volpetti S, Cabras MG, Di Renzo N, Merli F, Vallisa D, Spina M, Pascarella A, Latte G, Patti C, Fabbri A, Guarini A, Vitolo U, Hermine O, Kluin-Nelemans HC, Cortelazzo S, Dreyling M, Ladetto M. A Clinical Prognostic Model Based on Machine Learning from the Fondazione Italiana Linfomi (FIL) MCL0208 Phase III Trial. Cancers (Basel). 2021 Dec 31;14(1):188.
4. Mantoan B, Genuardi E, Ferrante M, Della Starza I, Ciabatti E, Grassi S, De Novi LA, Cavalli M, Mannu C, Gazzola A, Bomben R, Degan M, Alessandria B, Pott C, Delfau-Larue MH, García-Sanz R, Agostinelli C, Gattei V, Galimberti S, Del Giudice I, Gaidano G, Ladetto M, Ferrero S, **Drandi D**. Quality Assessment for PCR-based Minimal Residual Disease in Lymphoma: 10 Years of Cross-laboratory Standardization Process Within the Fondazione Italiana Linfomi MRD Network.
5. Ferrante M, Furlan D, Zibellini S, Borriero M, Candido C, Sahnane N, Uccella S, Genuardi E, Alessandria B, Bianchi B, Mora B, Grimaldi D, Defrancesco I, Jiménez C, Cavallo F, Ferrero D, Dogliotti I, Merli M, Varettoni M, Ferrero S, **Drandi D**. MYD88L265P Detection in IgM Monoclonal Gammopathies: Methodological Considerations for Routine Implementation. Diagnostics. 2021 Apr 26;11(5):779.
6. Genuardi E, Klous P, Mantoan B, **Drandi D**, Ferrante M, Cavallo F, Alessandria B, Dogliotti I, Grimaldi D, Ragaini S, Clerico M, Lo Schirico M, Saraci E, Yilmaz M, Zaccaria GM, Cortelazzo S, Vitolo U, Luminari S, Federico M, Boccadoro M, van Min M, Splinter E, Ladetto M, Ferrero S. Targeted locus amplification to detect molecular markers in mantle cell and follicular lymphoma. Hematol Oncol. 2021 Mar 20.
7. Della Starza I, De Novi LA, Cavalli M, Novelli N, Soscia R, Genuardi E, Mantoan B, **Drandi D**, Ferrante M, Monitillo L, Barbero D, Ciabatti E, Grassi S, Bomben R, Degan M, Gattei V, Galimberti S, Di Rocco A, Martelli M, Cortelazzo S, Guarini A, Foà R, Ladetto M, Ferrero S, Del Giudice I; Fondazione Italiana Linfomi (FIL) MRD Network. Hematol Oncol. Immunoglobulin kappa deleting element rearrangements are candidate targets for minimal residual disease evaluation in mantle cell lymphoma. 2020 Dec;38(5):698-704.
8. dMIQE Group: Huggett JF, Alexandra S Whale, Ward De Spiegelaere, Wim Trypsteen, Afif Abdel Nour, Young-Kyung Bae, Vladimir Benes, Daniel Burke, Megan Cleveland, Philippe Corbisier, Alison S Devonshire, Lianhua Dong, **Daniela Drandi**, Carole A Foy, Jeremy A Garson, Hua-Jun He, Jan Hellems, Mikael Kubista, Antoon Lievens, Mike G Makrigiorgos, Mojca Milavec, Reinhold D Mueller, Tania Nolan, Denise M O'Sullivan, Michael W Pfaffl, Stefan Rödiger, Erica L Romsos, Gregory L Shipley, Valerie Taly, Andreas Untergasser, Carl T Wittwer, Stephen A Bustin, Jo Vandesompele. The Digital MIQE Guidelines Update: Minimum Information for Publication of Quantitative Digital PCR Experiments for 2020. Clin Chem. 2020 Aug 1;66(8):1012-1029.
9. Elba S, Castellino A, Soriasio R, Castellino C, Bonferroni M, Mattei D, Strola G, **Drandi D**, Mordini N, Foglietta M, Rapezzi D, Celegghini I, Grasso M, Giordano F, Fraternali Orcioni G, Massaia M. Immunoglobulin M (IgM) multiple myeloma versus Waldenström macroglobulinemia: diagnostic challenges and therapeutic options: two case reports. J Med Case Rep. 2020 Jun 22;14(1):75
10. **Daniela Drandi**, Marion Alcantara, Ichrafe Benmaad, A. Söhlbrandt, Ludovic Lhermitte, GianMaria Zaccaria, Martina Ferrante, Elisa Genuardi, Barbara Mantoan, Patrick Villarese, Morgane Cheminant,

- Irene della Starza, Elena Ciabatti, Riccardo Bomben, Cristina Jimenez, Mary Callanan, Chrystelle Abdo, Cornelia Eckert, Vincent Ribrag, Sergio Cortelazzo, Martin Dreyling, Olivier Hermine, Marie-Hélène Delfau-Larue, Christiane Pott, Marco Ladetto, Simone Ferrero, Elizabeth Macintyre. Droplet digital PCR quantification of Mantle cell lymphoma follow-up samples from four prospective trials of the European MCL network. *Hemasphere*. 2020 Apr 3;4(2):e347. .
11. Lo Schirico M, Ferrante M, Dogliotti I, Zamò A, Ferrero B, Bertuzzo D, Benevolo G, Omedè P, Cavallo F, Ladetto M, Boccadoro M, **Drandi D**, Ferrero S. Droplet Digital PCR Assay for MYD88 L265P : Clinical Applications in Waldenström Macroglobulinemia. *Hemasphere*. 2020 Jan 3;4(1):e324.
 12. Della Starza I, Cavalli M, De Novi LA, Genuardi E, Mantoan B, **Drandi D**, Barbero D, Ciabatti E, Grassi S, Gazzola A, Mannu C, Agostinelli C, Piccaluga PP, Bomben R, Degan M, Gattei V, Guarini A, Foà R, Galimberti S, Ladetto M, Ferrero S, Del Giudice I; Fondazione Italiana Linfomi (FIL) MRD Network. Minimal residual disease (MRD) in non-Hodgkin lymphomas: Interlaboratory reproducibility on marrow samples with very low levels of disease within the FIL (Fondazione Italiana Linfomi) MRD Network. *Hematol Oncol*. 2019 Oct;37(4):368-374.
 13. Dogliotti I, **Drandi D**, Genuardi E, Ferrero S. New Molecular Technologies for Minimal Residual Disease Evaluation in B-Cell Lymphoid Malignancies. *J Clin Med*. 2018 Sep 18;7(9).
 14. **Drandi D**, Ferrero S, Ladetto M. Droplet Digital PCR for Minimal Residual Disease Detection in Mature Lymphoproliferative Disorders. *M. Methods Mol Biol*. 2018;1768:229-256.
 15. **Drandi D**, Genuardi E, Dogliotti I, Ferrante M, Jiménez C, Guerrini F, Schirico ML, Mantoan B, Muccio V, Lia G, Zaccaria GM, Omedè P, Passera R, Orsucci L, Benevolo G, Cavallo F, Galimberti S, Sanz RG, Boccadoro M, Ladetto M, Ferrero S. Highly sensitive MYD88L265P mutation detection by droplet digital polymerase chain reaction in Waldenström macroglobulinemia. *Haematologica*. 2018 Jun;103(6):1029-1037.
 16. Genuardi E, Barbero D, Dogliotti I, Mantoan B, **Drandi D**, Gambella M, Zaccaria GM, Monitillo L, Della Starza I, Cavalli M, De Novi LA, Ciabatti E, Grassi S, Gazzola A, Mannu C, Del Giudice I, Galimberti S, Agostinelli C, Piccaluga PP, Ladetto M, Ferrero S; Fondazione Italiana Linfomi (FIL) MRD Network. Ficoll-hypaque separation vs whole blood lysis: Comparison of efficiency and impact on minimal residual disease analysis. *Int J Lab Hematol*. 2018 Apr;40(2):201-208.
 17. Ghione P, Genuardi E, Rossi D, **Drandi D**, Mantoan B, Barbero D, Bernocco E, Monitillo L, Cerri M, Ruggeri M, Omedè P, Deambrogi C, De Paoli L, Passera R, Coscia M, Cavallo F, Massaia M, Boccadoro M, Gaidano G, Ladetto M, Ferrero S. Progressive telomere shortening is part of the natural history of chronic lymphocytic leukaemia and impacts clinical outcome: evidences from long term follow-up. *Br J Haematol*. 2017 Apr 2.
 18. Zaja F, Ferrero S, Stelitano C, Ferrari A, Salvi F, Arcari A, Musuraca G, Botto B, Spina M, Cellini C, Patti C, Liberati AM, Minotto C, Pileri SA, Ceccarelli M, Volpetti S, Ferranti A, **Drandi D**, Montechiarelo E, Ladetto M, Carmichael J, Fanin R. Second-line rituximab, lenalidomide, and bendamustine in mantle cell lymphoma: a phase II clinical trial of the Fondazione Italiana Linfomi. *Haematologica*. 2017 May;102(5):e203-e206.
 19. Griggio V, Mandili G, Vitale C, Capello M, Macor P, Serra S, Castella B, Peola S, Foglietta M, **Drandi D**, Omedè P, Sblattero D, Cappello P, Chiarle R, Deaglio S, Boccadoro M, Novelli F, Massaia M, Coscia M. Humoral immune responses toward tumor-derived antigens in previously untreated patients with chronic lymphocytic leukemia. *Oncotarget*. 2017 Jan 10;8(2):3274-3288.
 20. Oliva S, Gambella M, Gilestro M, Muccio VE, Gay F, **Drandi D**, Ferrero S, Passera R, Pautasso C, Bernardini A, Genuardi M, Patriarca F, Saraci E, Petrucci MT, Pescosta N, Liberati AM, Caravita T, Conticello C, Rocci A, Musto P, Boccadoro M, Palumbo A, Omedè P. Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysis. *Oncotarget*. 2017 Jan 24;8(4):5924-5935.
 21. Ladetto M, Ferrero S, **Drandi D**, Festuccia M, Patriarca F, Mordini N, Cena S, Benedetto R, Guarona G, Ferrando F, Brunello L, Ghione P, Boccasavia V, Fanin R, Omedè P, Giaccone L, Palumbo A, Passera R, Boccadoro M, Bruno B. Prospective molecular monitoring of minimal residual disease after non-myeloablative allografting in newly diagnosed multiple myeloma. *Leukemia*. 2015 Oct 6. doi: 10.1038/leu.2015.269.
 22. **Drandi D**, Kubiczkova-Besse L, Ferrero S, Dani N, Passera R, Mantoan B, Gambella M, Monitillo L, Saraci E, Ghione P, Genuardi E, Barbero D, Omedè P, Barberio D, Hajek R, Vitolo U, Palumbo A, Cortelazzo S, Boccadoro M, Inghirami G, Ladetto M. Minimal Residual Disease Detection by Droplet Digital PCR in Multiple Myeloma, Mantle Cell Lymphoma, and Follicular Lymphoma: A Comparison with Real-Time PCR. *J Mol Diagn*. 2015 Nov;17(6):652-60.
 23. Rigoni M, Riganti C, Vitale C, Griggio V, Campia I, Robino M, Foglietta M, Castella B, Sciancalepore P, Buondonno I, **Drandi D**, Ladetto M, Boccadoro M, Massaia M, Coscia M. Simvastatin and downstream

- inhibitors circumvent constitutive and stromal cell-induced resistance to doxorubicin in IGHV unmutated CLL cells. *Oncotarget*. 2015 Oct 6;6(30):29833-46.
24. Ferrero S, Ladetto M, **Drandi D**, Cavallo F, Genuardi E, Urbano M, Caltagirone S, Grasso M, Rossini F, Guglielmelli T, Cangialosi C, Liberati AM, Callea V, Carovita T, Crippa C, De Rosa L, Pisani F, Falcone AP, Pregno P, Oliva S, Terragna C, Musto P, Passera R, Boccadoro M, Palumbo A. Long-term results of the GIMEMA VEL-03-096 trial in MM patients receiving VTD consolidation after ASCT: MRD kinetics' impact on survival. *Leukemia*. 2014 Jul 16. doi: 10.1038/leu.2014.219. [Epub ahead of print]
 25. Rocci A, Gambella M, Aschero S, Baldi I, Trusolino L, Cavallo F, Gay F, Larocca A, Magarotto V, Omedè P, Isaia G, Bertotti A, Liberati AM, Catalano L, De Rosa L, Musto P, Vallone R, Falcone A, **Drandi D**, Ladetto M, Comoglio PM, Boccadoro M, Palumbo A. MET dysregulation is a hallmark of aggressive disease in multiple myeloma patients. *Br J Haematol*. 2014 Mar;164(6):841-50.
 26. Ladetto M, Brüggemann M, Monitillo L, Ferrero S, Pepin F, **Drandi D**, *et al*. Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders. *Leukemia* 2013 Dec.
 27. Ferrero S, Monitillo L, Mantoan B, Barbero D, Genuardi E, Barbiero S, Bernocco E, Caracciolo D, Ruella M, **Drandi D**, Zanni M, Renna F, Lobetti Bodoni C, Gueli A, Passera R, Musto P, Boccadoro M, Tarella C, Ladetto M. Rituximab-based pre-emptive treatment of molecular relapse in follicular and mantle cell lymphoma. *Ann Hematol*. 2013 Nov;92(11):1503-11.
 28. Lobetti-Bodoni C, Mantoan B, Monitillo L, Genuardi E, **Drandi D**, Barbero D, *et al*. Clinical implications and prognostic role of minimal residual disease detection in follicular lymphoma. *Ther Adv Hematol* 2013 Jun; 4(3): 189-198.
 29. Ladetto M, Lobetti-Bodoni C, Mantoan B, Ceccarelli M, Boccomini C, Genuardi E, *et al*. Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program. *Blood* 2013 Nov; 122(23): 3759-3766.
 30. Coscia M, Vitale C, Peola S, Foglietta M, Rigoni M, Griggio V, Castella B, Angelini D, Chiaretti S, Riganti C, Guarini A, Drandi D, Ladetto M, Bosia A, Foà R, Battistini L, Boccadoro M, Fournié JJ, Massaia M. Dysfunctional Vγ9Vδ2 T cells are negative prognosticators and markers of dysregulated mevalonate pathway activity in chronic lymphocytic leukemia cells. *Blood*. 2012 Oct 18;120(16):3271-9.
 31. Lobetti-Bodoni C, Ferrero D, Genuardi E, Passera R, Bernocco E, Sia D, Grignani G, Crisà E, Monitillo L, Rocci A, Drandi D, Gai V, Zanni M, Boi M, Isaia G, Barbero D, Lunghi M, Abruzzese E, Radaelli F, Pini M, Pregno P, Carlo-Stella C, Gaidano G, Boccadoro M, Ladetto M. Telomere loss in Philadelphia-negative hematopoiesis after successful treatment of chronic myeloid leukemia: evidence for premature aging of the myeloid compartment. *Mech Ageing Dev*. 2012 Jul;133(7):479-88.
 32. Ferrero S, Capello D, Svaldi M, Boi M, Gatti D, Drandi D, Rossi D, Barbiero S, Mantoan B, Mantella E, Zanni M, Ghione P, Larocca A, Passera R, Bertoni F, Gattei V, Forconi F, Laurenti L, Del Poeta G, Marasca R, Cortelazzo S, Gaidano G, Palumbo A, Boccadoro M, Ladetto M. Multiple myeloma shows no intra-disease clustering of immunoglobulin heavy chain genes. *Haematologica*. 2012 Jun;97(6):849-53.
 33. Genome-wide DNA profiling better defines the prognosis of chronic lymphocytic leukaemia. Rinaldi A, Mian M, Kwee I, Rossi D, Deambrogi C, Mensah AA, Forconi F, Spina V, Cencini E, Drandi D, Ladetto M, Santachiara R, Marasca R, Gattei V, Cavalli F, Zucca E, Gaidano G, Bertoni F. *Br J Haematol*. 2011 Sep;154(5):590-9.
 34. Ferrero S, Drandi D, Mantoan B, Ghione P, Omedè P, Ladetto M. Minimal residual disease detection in lymphoma and multiple myeloma: impact on therapeutic paradigms. *Hematol Oncol* 2011 Dec; 29(4): 167-176.
 35. Coscia M, Pantaleoni F, Riganti C, Vitale C, Rigoni M, Peola S, Castella B, Foglietta M, Griggio V, Drandi D, Ladetto M, Bosia A, Boccadoro M, Massaia M. IGHV unmutated CLL B cells are more prone to spontaneous apoptosis and subject to environmental prosurvival signals than mutated CLL B cells. *Leukemia*. 2011 May;25(5):828-37.
 36. Ladetto M, Pagliano G, Ferrero S, Cavallo F, Drandi D, Santo L, *et al*. Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma. *J Clin Oncol* 2010 Apr; 28(12): 2077-2084.
 37. Ladetto M, De Marco F, Benedetti F, Vitolo U, Patti C, Rambaldi A, *et al*. Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage. *Blood* 2008 Apr; 111(8): 4004-4013.
 38. Ricca I, Rocci A, Drandi D, Francese R, Compagno M, Lobetti Bodoni C, De Marco F, Astolfi M, Monitillo L, Vallet S, Calvi R, Ficara F, Omedè P, Rosato R, Gallamini A, Marinone C, Bergui L, Boccadoro M, Tarella C, Ladetto M. Telomere length identifies two different prognostic subgroups among VH-unmutated B-cell chronic lymphocytic leukemia patients. *Leukemia*. 2007 Apr;21(4):697-705. Epub 2007 Feb 15
 39. Ladetto M, Magni M, Pagliano G, De Marco F, Drandi D, Ricca I, Astolfi M, Matteucci P, Guidetti A, Mantoan B, Bodoni CL, Zanni M, Boccadoro M, Gianni AM, Tarella C. Rituximab induces effective

- clearance of minimal residual disease in molecular relapses of mantle cell lymphoma. *Biol Blood Marrow Transplant*. 2006 Dec;12(12):1270-6.
40. Ladetto M, Mantoan B, De Marco F, Drandi D, Aguzzi C, Astolfi M, Vallet S, Ricca I, Dell' Aquila M, Pagliano G, Monitillo L, Pollio B, Santo L, Cristiano C, Rocci A, Francese R, Bodoni CL, Borchellini A, Schinco P, Boccadoro M, Tarella C. Cells carrying nonlymphoma-associated bcl-2/IgH rearrangements (NLABR) are phenotypically related to follicular lymphoma and can establish as long-term persisting clonal populations. *Exp Hematol*. 2006 Dec;34(12):1680-6.
 41. Majolino I, Ladetto M, Locasciulli A, Drandi D, Benedetti F, Gallamini A, Chisesi T, De Blasio A, Boccadoro M, Tarella C. High-Risk Fludarabine-Pretreated B-Cell Chronic Lymphocytic Leukemia's High Response Rate Following Sequential DHAP and Alemtuzumab Administration Though in Absence of Molecular Remission. *Med Oncol*. 2006;23(3):359-68
 42. Ladetto M, Vallet S, Trojan A, Dell'Aquila M, Monitillo L, Rosato R, Santo L, Drandi D, Bertola A, Falco P, Cavallo F, Ricca I, De Marco F, Mantoan B, Bode-Lesniewska B, Pagliano G, Francese R, Rocci A, Astolfi M, Compagno M, Mariani S, Godio L, Marino L, Ruggeri M, Omedè P, Palumbo A, Boccadoro M. Cyclooxygenase-2 (COX-2) is frequently expressed in multiple myeloma and is an independent predictor of poor outcome. *Blood*. 2005 Jun 15;105(12):4784-91. Epub 2005 Feb 24.
 43. Gricks CS, Zahrieh D, Zauls AJ, Gorgun G, Drandi D, Mauere K, Neuberg D, Gribben JG. Differential regulation of gene expression following CD40 activation of leukemic compared to healthy B cells. *Blood*. 2004 May 25 [Epub ahead of print]
 44. Ladetto M, Compagno M, Ricca I, Pagano M, Rocci A, Astolfi M, Drandi D, Francia Di Celle P, Dell Aquila M, Mantoan B, Vallet S, Pagliano G, De Marco F, Francese R, Santo L, Cuttica A, Marinone C, Boccadoro M, Tarella C. Telomere length correlates with histopathogenesis according to the germinal center in mature B-cell lymphoproliferative disorders. *Blood*. 2004 Jun 15;103(12):4644-9.
 45. Ladetto M, Mantoan B, Ricca I, Astolfi M, Drandi D, Compagno M, Vallet S, dell'Aquila M, Alfarano A, Rossatto P, Rocci A, Vitolo U, Corradini P, Boccadoro M, Tarella C. Recurrence of Bcl-2/IgH polymerase chain reaction positivity following a prolonged molecular remission can be unrelated to the original follicular lymphoma clone. *Exp Hematol*. 2003 Sep;31(9):784-8.
 46. Ladetto M, Drandi D, Compagno M, Astolfi M, Volpato F, Voena C, Novarino A, Pollio B, Addeo A, Ricca I, Falco P, Cavallo F, Vallet S, Corradini P, Pileri A, Tamponi G, Palumbo A, Bertetto O, Boccadoro M, Tarella C. PCR-detectable nonneoplastic Bcl-2/IgH rearrangements are common in normal subjects and cancer patients at diagnosis but rare in subjects treated with chemotherapy. *J Clin Oncol*. 2003 Apr 1;21(7):1398-403.
 47. Ladetto M, Corradini P, Vallet S, Benedetti F, Vitolo U, Martelli M, Brugiattelli M, Coser P, Perrotti A, Majolino I, Fioritoni G, Morandi S, Musso M, Zambello R, Chisesi T, Di Renzo N, Vivaldi P, De Crescenzo A, Gallamini A, Salvi F, Santini G, Boccomini C, Sorio M, Astolfi M, Drandi D, Pileri A, Tarella C. High rate of clinical and molecular remissions in follicular lymphoma patients receiving high-dose sequential chemotherapy and autografting at diagnosis: a multicenter, prospective study by the Gruppo Italiano Trapianto Midollo Osseo (GITMO). *Blood*. 2002 Sep 1;100(5):1559-65.
 48. Ladetto M, Omedè P, Sametti S, Donovan JW, Astolfi M, Drandi D, Volpato F, Giaccone L, Giarretta F, Palumbo A, Bruno B, Pileri A, Gribben JG, Boccadoro M. Real-time polymerase chain reaction in multiple myeloma: quantitative analysis of tumor contamination of stem cell harvests. *Exp Hematol*. 2002 Jun;30(6):529-36.
 49. Ladetto M, Sametti S, Astolfi M, Corradini P, Ricca I, Drandi D, Pileri A, Tarella C. Central nervous system relapse in a patient with mantle cell lymphoma in continuous clinical and molecular remission at six years since autografting. *Leuk Lymphoma*. 2001 Feb;40(5-6):679-82.
 50. Ladetto M, Sametti S, Donovan JW, Ferrero D, Astolfi M, Mitterer M, Ricca I, Drandi D, Corradini P, Coser P, Pileri A, Gribben JG, Tarella C. A validated real-time quantitative PCR approach shows a correlation between tumor burden and successful ex vivo purging in follicular lymphoma patients. *Exp Hematol*. 2001 Feb;29(2):183-93.

In compliance with the Italian legislative Decree no. 196 dated 30/06/2003, and art. 13 of EU Regulation 2016/679 concerning the protection of individuals personal data, I hereby authorize to use and process my personal details contained in this document.

TORINO 22/04/2022

